A new type of vaccine that can be stored at warmer temperatures, removing the need for refrigeration, has been developed for mosquito-borne virus Chikungunya in a major advance in vaccine technology.
The findings, published in Science Advances today [Wednesday 25 September], reveal exceptionally promising results for the Chikungunya vaccine candidate, which has been engineered using a synthetic protein scaffold that could revolutionise the way vaccines are designed, produced and stored.
Infectious diseases continue to plague populations worldwide. Among the means at our disposal to counter this threat, vaccination has proven to be exceptionally powerful. Smallpox has been eradicated, measles, polio and tetanus constrained from the world by vaccination. However, severe challenges to human health persist, evidenced by epidemics caused by Ebola, Zika and others. This is particularly severe in developing countries which often lack adequate infrastructure and resources to prevent or manage outbreaks, bringing about disruption and damage in affected communities and massive economic shortfall.
A recent example is Chikungunya, a virus transmitted by the bite of an infected mosquito. The disease causes crippling headache, vomiting, swelling of limbs and can lead to death. Even if a fever ends abruptly, chronic symptoms such as intense joint pain, insomnia and extreme prostration remain. Formerly confined to sub-Saharan Africa, Chikungunya has recently spread worldwide as its mosquito host leaves its natural habitat due to deforestation and climate change, with recent outbreaks in USA and Europe causing alarm.
Researchers from the University of Bristol and the French National Centre for Scientific Research (CNRS) in Grenoble, France, teamed up with computer technology giant Oracle to find a way to make vaccines that are thermostable (able to withstand warm temperatures), can be designed quickly and are easily produced.
“We were working with a protein that forms a multimeric particle resembling a virus but is completely safe, because it has no genetic material inside, said Pascal Fender, expert virologist at CNRS. “Completely by chance, we discovered that this particle was incredibly stable even after months, without refrigeration.”
“This particle has a very flexible, exposed surface that can be easily engineered, added Imre Berger, Director of the Max Planck-Bristol Centre for Minimal Biology in Bristol. “We figured that we could insert small, harmless bits of Chikungunya to generate a virus-like mimic we could potentially use as a vaccine.”
To validate their design, the scientists employed cryo-electron microscopy, a powerful new technique recently installed in Bristol’s state-of-the-art microscopy facility headed by Christiane Schaffitzel, co-author of the study. Cryo-EM yields very large data sets from which the structure of a sample can be determined at near atomic resolution, requiring massive parallel computing.
Enabled by Oracle’s high-performance cloud infrastructure, the team developed a novel computational approach to create an accurate digital model of the synthetic vaccine. University of Bristol IT specialists Christopher Woods and Matt Williams, together with colleagues at Oracle, implemented software packages seamlessly on the cloud in this pioneering effort. Christopher explained: “We were able to process the large data sets obtained by the microscope on the cloud in a fraction of the time and at much lower cost than previously thought possible.”
“Researchers have had a long tradition of building and installing their own super computers on-premises, but cloud computing is allowing them to run large data sets in record time, with fast connectivity and low latency. This is helping them crunch data and make scientific breakthroughs much faster. Going forward, technologies like machine learning and cloud computing will play a significant part in the scientific world, and we are delighted we could help the researchers with this important discovery,” added Phil Bates, leading cloud architect at Oracle.
The particles the scientists designed yielded exceptionally promising results in animal studies, soundly setting the stage for a future vaccine to combat Chikungunya disease.
“We were thoroughly delighted,” continued Imre Berger. “Viruses are waiting to strike, and we need to have the tools ready to tackle this global threat. Our vaccine candidate is easy to manufacture, extremely stable and elicits a powerful immune response. It can be stored and transported without refrigeration to countries and patients where it is most needed. Intriguingly, we can now rapidly engineer similar vaccines to combat many other infectious diseases just as well.”
“It really ticks a lot of boxes,” concluded Fred Garzoni, founder of Imophoron Ltd, a Bristol biotech start-up developing new vaccines derived from the present work. “Many challenges in the industry require innovative solutions, to bring powerful new vaccines to patients. Matching cutting-edge synthetic biology with cloud computing turned out to be a winner.”
The Latest on: Synthetic vaccines
via Google News
The Latest on: Synthetic vaccines
- New vaccine to stop bovine TB developed: Studyon November 29, 2019 at 5:17 am
The study, published in the journal Scientific Reports, revealed that the research team from University of Surrey created a vaccine that is compatible with a synthetic form of the tuberculin skin test ...
- UK scientists develop new novel bovine TB vaccineon November 29, 2019 at 3:05 am
For the first time a vaccine has been created that is compatible with a synthetic form of the tuberculin skin test (PPD). This is a legally required test used for the surveillance of TB in cattle ...
- Peptide-based vaccine successfully induces protective immunity against canine visceral leishmaniasison November 29, 2019 at 2:13 am
25 The results of the present study will help guide research towards peptide-based synthetic vaccines, as these have many advantages in terms of safety, efficacy and cross-protection, with ...
- Pediatric Vaccines Market Detailed Analysis of Current Industry Figures with Forecasts Growth By 2021on November 28, 2019 at 9:28 pm
Nov 29, 2019 (AmericaNewsHour) -- The global pediatric vaccines market is segmented into product type such as synthetic vaccines, dendritic cells vaccines, toxoid vaccines, live attenuated vaccines, ...
- New vaccine against bovine TBon November 28, 2019 at 3:08 pm
This test, unlike PPD, will show a positive result if the animal is infected but not if it has been vaccinated, because the vaccine lacks the synthetic PPD proteins. Now it was time to check how well ...
- Bovine TB novel vaccine developed by University of Surrey scientistson November 28, 2019 at 6:53 am
Agricultural Research Service/USDA Publishing their findings in the journal Scientific Reports, researchers reveal they have for the first time created a vaccine that is compatible with a synthetic ...
- New vaccine will stop the spread of bovine tuberculosison November 28, 2019 at 2:03 am
Publishing their findings in the journal Scientific Reports, researchers reveal they have for the first time created a vaccine that is compatible with a synthetic form of the tuberculin skin test (PPD ...
- New method accelerates development of protein therapeuticson November 27, 2019 at 10:26 am
"This is an exciting new method that accelerates the design and engineering of potential medicines and vaccines using glycosylation," said Michael Jewett, the Charles Deering McCormick Professor of ...
- Tailoring vaccines for older people and the very youngon November 27, 2019 at 6:09 am
The researchers hope that a trial in Gambia, due to be completed in 2021, will show whether and how the BCG vaccine might do the same in infants. Levy’s team is also on the hunt for synthetic ...
- Poultry pardons, synthetic frogs, Freedom Rocks: News from around our 50 stateson November 25, 2019 at 11:54 pm
The state Department of Health on Friday issued a notice telling students they need to be immunized with at least two doses of the mumps vaccine or sit out of class for 26 days ... J.W. Mitchell High ...
via Bing News